Droxidopa
- Generic Name
- Droxidopa
- Brand Names
- Northera
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO5
- CAS Number
- 23651-95-8
- Unique Ingredient Identifier
- J7A92W69L7
- Background
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopa...
- Indication
For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainti...
- Associated Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH)
- Associated Therapies
- -
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 225
- Registration Number
- NCT01176240
- Locations
- ๐บ๐ธ
Northwest Neuro Specialists P.L.L.C., Tucson, Arizona, United States
๐บ๐ธHartford Hospital, Hartford, Connecticut, United States
๐บ๐ธEastern Connecticut Neurology Specialists, Manchester, Connecticut, United States
Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa
- Conditions
- Interventions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2013-03-20
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT01149629
- Locations
- ๐บ๐ธ
Cetero Research, Fargo, North Dakota, United States
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
- Conditions
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 350
- Registration Number
- NCT01132326
Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT00977171
- Locations
- ๐บ๐ธ
7421 Carmel Executive Park Drive, Ste. 320, Charlotte, North Carolina, United States
Long Term Treatment With L-DOPS
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Vanderbilt University
- Registration Number
- NCT00889135
- Locations
- ๐บ๐ธ
Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 263
- Registration Number
- NCT00782340
- Locations
- ๐จ๐ฆ
Movment Disorder Clinic Deer lodge Centre, Winnipeg, Manitoba, Canada
๐บ๐ธMayo Clinic-Arizona, Scottsdale, Arizona, United States
๐จ๐ฆIRCM, Montreal, Quebec, Canada
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 103
- Registration Number
- NCT00738062
- Locations
- ๐บ๐ธ
Saint Mary of Nazareth Hospital Center, Chicago, Illinois, United States
๐บ๐ธUniversity Hospitals Case Medical Center, Cleveland, Ohio, United States
๐บ๐ธCleveland Clinic, Cleveland, Ohio, United States
Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT00657046
- Locations
- ๐บ๐ธ
Rogue Valley Dialysis, Medford, Oregon, United States
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 181
- Registration Number
- NCT00633880
- Locations
- ๐บ๐ธ
University of Maryland, Baltimore, Maryland, United States
๐บ๐ธThe Parkinson's Institute, Sunnyvale, California, United States
๐บ๐ธParkinson's Disease & Movment Disorder Center, Boca Raton, Florida, United States
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
- Conditions
- Interventions
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2014-07-17
- Target Recruit Count
- 14
- Registration Number
- NCT00547911
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.